HomeBT3 • FRA
Lineage Cell Therapeutics Inc
€0.62
Peb 6, 7:32:04 AM GMT+1 · EUR · FRA · Disclaimer
StockSegurong nakalista sa DE
Nakaraang pagsara
€0.62
Sakop ng taon
€0.46 - €1.33
Market cap
161.20M USD
Average na Volume
452.00
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(USD)Set 2024Y/Y na pagbabago
Kita
3.78M203.29%
Gastos sa pagpapatakbo
4.41M9.13%
Net na kita
-3.03M57.33%
Net profit margin
-80.2985.93%
Kita sa bawat share
-0.0250.37%
EBITDA
-3.70M43.35%
Aktuwal na % ng binabayarang buwis
Kabuuang asset
Kabuuang sagutin
(USD)Set 2024Y/Y na pagbabago
Cash at mga panandaliang investment
32.71M-20.86%
Kabuuang asset
96.59M-9.00%
Kabuuang sagutin
31.80M-19.48%
Kabuuang equity
64.79M
Natitirang share
188.84M
Presyo para makapag-book
1.76
Return on assets
-9.63%
Return on capital
-13.98%
Net change in cash
(USD)Set 2024Y/Y na pagbabago
Net na kita
-3.03M57.33%
Cash mula sa mga operasyon
-5.79M-14.89%
Cash mula sa pag-invest
3.89M83.22%
Cash mula sa financing
-3.00K-100.37%
Net change in cash
-1.86M23.86%
Malayang cash flow
-2.27M12.27%
Tungkol
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Itinatag
1990
Mga Empleyado
72
Search
I-clear ang paghahanap
Isara ang paghahanap
Mga app ng Google
Pangunahing menu